adMare BioInnovations, Canada’s global life sciences venture, invites you to join us on Thursday, December 10 at 11:00 am (EST), for the unveiling of the six exciting start-ups selected for our new…
Read More
COVID-19 may be keeping us from getting on planes and meeting in person, but it’s not stopping us from continuing to build Canada’s life sciences industry from sea to sea,…
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
